Expand ENTA Menu
ENTA MENU

ENTA Latest Press Releases

-- January 8, 2026 --

Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook Business Wire 7:00 AM

-- January 5, 2026 --

Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference Business Wire 7:00 AM

-- November 17, 2025 --

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025 Business Wire 4:01 PM

-- November 4, 2025 --

Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences Business Wire 7:00 AM

-- October 20, 2025 --

Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek 2025 Business Wire 7:00 AM

-- October 7, 2025 --

Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek 2025 Business Wire 7:00 AM

-- October 2, 2025 --

Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares Business Wire 4:01 PM

-- September 30, 2025 --

Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock Business Wire 9:00 PM
Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire 4:11 PM

-- September 29, 2025 --

Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults Business Wire 6:30 AM

-- September 26, 2025 --

Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults Business Wire 4:01 PM

-- September 3, 2025 --

Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mellett Jr. Business Wire 6:00 AM

-- August 21, 2025 --

Enanta Pharmaceuticals to Participate in September Investor Conferences Business Wire 7:00 AM

-- August 20, 2025 --

Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union Business Wire 7:00 AM

-- August 11, 2025 --

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025 Business Wire 4:02 PM
Market Data Delayed 15 Minutes